PSME1

Across TCGA pan-cancer cohorts, PSME1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSME1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSME1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PSME1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where PSME1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.981	0.575	.001	18	view →
PDAC	OS	Quartile	All	0.657	0.447	.010	11	view →
GBM	DFS	Quartile	All	0.644	0.846	.020	8	view →
HNSC	DFS	Quartile	II,III,IV	0.903	1.000	.032	5	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.077	.024	4	view →
LSCC	DFS	Quartile	All	1.000	0.524	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSME1–LUAD (DFS)

Open the LUAD breakdown →